Pregnancy Outcomes in Patients Treated with Bosutinib
Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Elisabetta Abruzzese, Liza DeAnnuntis, Tim H. Brümmendorf
Abstract
AIM: Preclinical studies have shown reproductive toxicity with bosutinib, but little is known about its effects during conception or pregnancy in humans. METHODS: Pregnancy cases in patients receiving bosutinib were identified from the Pfizer safety database. RESULTS: Thirty-three pregnancy reports were identified. Sixteen cases of maternal exposure: six live births, four abortions and six with unknown outcomes. Seventeen instances of paternal exposure: nine live births, five abortions and three with unknown outcomes. CONCLUSION: Adverse effects of bosutinib exposure at conception or during pregnancy in humans cannot be excluded, particularly if therapy is not interrupted upon recognition of pregnancy. Contraceptive use is recommended for female patients receiving bosutinib, and patients should be made aware of the potential risks associated with bosutinib use during pregnancy.